Cargando…

Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care

BACKGROUND: Shoulder pain is a very common presentation in primary care. Evidence of benefit for subacromial corticosteroid injection is inconclusive and confined largely to studies with short follow-up. We plan a large, definitive, primary-care-based trial to determine efficacy and safety in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Holt, Tim A, Mant, David, Carr, Andrew, Gwilym, Stephen, Beard, David, Toms, Christy, Yu, Ly-Mee, Rees, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878869/
https://www.ncbi.nlm.nih.gov/pubmed/24325987
http://dx.doi.org/10.1186/1745-6215-14-425
_version_ 1782297881235947520
author Holt, Tim A
Mant, David
Carr, Andrew
Gwilym, Stephen
Beard, David
Toms, Christy
Yu, Ly-Mee
Rees, Jonathan
author_facet Holt, Tim A
Mant, David
Carr, Andrew
Gwilym, Stephen
Beard, David
Toms, Christy
Yu, Ly-Mee
Rees, Jonathan
author_sort Holt, Tim A
collection PubMed
description BACKGROUND: Shoulder pain is a very common presentation in primary care. Evidence of benefit for subacromial corticosteroid injection is inconclusive and confined largely to studies with short follow-up. We plan a large, definitive, primary-care-based trial to determine efficacy and safety in patients with rotator cuff tendinopathy, and conducted a pilot trial to explore feasibility. METHODS: Six general practitioners (GPs) from Oxfordshire, UK underwent update training in assessing painful shoulders and injecting the subacromial space. Each then recruited patients aged 35 to 74 years from primary care complaining of shoulder pain lasting no more than 6 months. Eligible participants were randomized to receive either methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml), or lidocaine 1% alone (total volume 1 ml), injected into the subacromial space. The participants were blinded to treatment allocation. Feasibility outcomes were rates of recruitment, withdrawal, adherence to the protocol, completeness of follow-up, and success of patient masking. Clinical outcomes were the Oxford Shoulder Score (OSS) at baseline and at 4 and 12 weeks, and responses to three satisfaction questions at 2, 4 and 12 weeks. Outcome data were collected by postal questionnaires. RESULTS: A total of 40 participants were randomized (80% of the target 50 participants) over 26 weeks giving an overall recruitment rate of 1.5 participants per week. Rates of follow-up were maintained to a high level for the full 12 weeks. Four participants requested a ‘rescue’ corticosteroid injection but no patients withdrew. The trial GPs gave high scores for their confidence that the patient had remained blinded to treatment allocation during the procedure. The OSS at 4 and 12 weeks and the responses to the satisfaction questions are reported. CONCLUSIONS: It is feasible to recruit participants with shoulder pain in the primary care setting for a blinded, randomized trial of corticosteroid injection. Online randomization of participants from the practice is also feasible, and postal questionnaires provide an effective means of gathering outcome data in this area of study. The lessons learned from this pilot will usefully inform the design of a large, definitive efficacy trial in primary care. TRIAL REGISTRATION: Current Clinical Trials ISRCTN82357435
format Online
Article
Text
id pubmed-3878869
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38788692014-01-03 Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care Holt, Tim A Mant, David Carr, Andrew Gwilym, Stephen Beard, David Toms, Christy Yu, Ly-Mee Rees, Jonathan Trials Research BACKGROUND: Shoulder pain is a very common presentation in primary care. Evidence of benefit for subacromial corticosteroid injection is inconclusive and confined largely to studies with short follow-up. We plan a large, definitive, primary-care-based trial to determine efficacy and safety in patients with rotator cuff tendinopathy, and conducted a pilot trial to explore feasibility. METHODS: Six general practitioners (GPs) from Oxfordshire, UK underwent update training in assessing painful shoulders and injecting the subacromial space. Each then recruited patients aged 35 to 74 years from primary care complaining of shoulder pain lasting no more than 6 months. Eligible participants were randomized to receive either methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml), or lidocaine 1% alone (total volume 1 ml), injected into the subacromial space. The participants were blinded to treatment allocation. Feasibility outcomes were rates of recruitment, withdrawal, adherence to the protocol, completeness of follow-up, and success of patient masking. Clinical outcomes were the Oxford Shoulder Score (OSS) at baseline and at 4 and 12 weeks, and responses to three satisfaction questions at 2, 4 and 12 weeks. Outcome data were collected by postal questionnaires. RESULTS: A total of 40 participants were randomized (80% of the target 50 participants) over 26 weeks giving an overall recruitment rate of 1.5 participants per week. Rates of follow-up were maintained to a high level for the full 12 weeks. Four participants requested a ‘rescue’ corticosteroid injection but no patients withdrew. The trial GPs gave high scores for their confidence that the patient had remained blinded to treatment allocation during the procedure. The OSS at 4 and 12 weeks and the responses to the satisfaction questions are reported. CONCLUSIONS: It is feasible to recruit participants with shoulder pain in the primary care setting for a blinded, randomized trial of corticosteroid injection. Online randomization of participants from the practice is also feasible, and postal questionnaires provide an effective means of gathering outcome data in this area of study. The lessons learned from this pilot will usefully inform the design of a large, definitive efficacy trial in primary care. TRIAL REGISTRATION: Current Clinical Trials ISRCTN82357435 BioMed Central 2013-12-10 /pmc/articles/PMC3878869/ /pubmed/24325987 http://dx.doi.org/10.1186/1745-6215-14-425 Text en Copyright © 2013 Holt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Holt, Tim A
Mant, David
Carr, Andrew
Gwilym, Stephen
Beard, David
Toms, Christy
Yu, Ly-Mee
Rees, Jonathan
Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title_full Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title_fullStr Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title_full_unstemmed Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title_short Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
title_sort corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878869/
https://www.ncbi.nlm.nih.gov/pubmed/24325987
http://dx.doi.org/10.1186/1745-6215-14-425
work_keys_str_mv AT holttima corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT mantdavid corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT carrandrew corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT gwilymstephen corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT bearddavid corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT tomschristy corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT yulymee corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare
AT reesjonathan corticosteroidinjectionforshoulderpainsingleblindrandomizedpilottrialinprimarycare